Ayala Pharmaceuticals Inc (ADXS)

[exel_mm]

By another year, I'm thinking we shouldn't be surprised to see an early BO. I suspect that post EU approval, a buyout will quickly follow. The other, left-field scenario, is an early "cheap" BO just prior to EU submission, which is much less likely.

I hope that DOC does not settle for anything below 8B, but I my gut says the price will be around 4 or 5B, sometime in 2018 (or early 2019 if EU approval is late 2018 Q4).

Bottom-line, I don't think this company has 2 years of runaway as the entity "Advaxis". The platform is simply too compelling not to be gobbled up.